Drug Topics
APRIL 5, 2024
Eric Fromhart, co-founder and chief growth officer at Aventi Health, talked about the importance of the 340B drug pricing program at the 2024 AAP annual conference.
STAT
APRIL 5, 2024
The Centers for Disease Control and Prevention urged medical practitioners on Friday to be on the lookout for people who might have contracted H5N1 bird flu from cows. The agency also urged state health departments to rapidly assess any suspected human cases, and recommended that dairy farms with confirmed or suspected outbreaks require workers to use personal protective equipment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
APRIL 5, 2024
With drug price negotiations for 10 drugs through the Inflation Reduction Act (IRA) set to take effect in 2026, researchers simulated the extent of Medicare savings.
STAT
APRIL 5, 2024
News that H5N1 avian influenza has breached another mammalian species — this time dairy cows — has taken the flu science community aback. Though cows previously had been seen to be susceptible to human flu viruses , and could be experimentally infected with H5 in a lab, the absence of cow involvement until now in H5’s nearly 30-year history lulled scientists into thinking the species was outside the virus’s remit.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
APRIL 5, 2024
In 4 posters presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024, researchers addressed pharmacists’ role in managing patients’ anticancer medications.
STAT
APRIL 5, 2024
Dogs, our sunny, selfless shadows, crave little more than a daily walk, a treat or two, and their human’s happiness. But increasingly, their own happiness is the topic of concern in veterinarian offices, dog parks, and internet forums. Prozac prescriptions for dogs are on the rise, veterinarians across the country acknowledge, along with a myriad of cheaper generic mood stabilizers sold for humans but applied to pets’ separation anxiety, socialization fears, biting habits, or other
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
APRIL 5, 2024
Greg Baker, CEO of AffirmedRx, discusses the DRUG Act legislation and its potential impact on curbing rising drug costs through PBM reform.
Fierce Healthcare
APRIL 5, 2024
Four in 10 therapists are planning to raise their fees in 2024, a new survey has found. | In last year’s report, 64% of therapists said they were planning to raise their fees in 2023. Yet only a third did, which could be explained by therapists' desire to remain accessible to patients.
STAT
APRIL 5, 2024
Johnson & Johnson on Friday announced it would acquire heart device firm Shockwave Medical for $13.1 billion. It’s J&J’s second major deal in the cardiovascular space in two years, following its 2022 purchase of Abiomed for $16.6 billion. Shockwave Medical’s device works to break down calcified plaque in the coronary and peripheral arteries using sonic pressure waves — a treatment called intravascular lithotripsy.
Fierce Healthcare
APRIL 5, 2024
Amwell could find itself dropped from the New York Stock Exchange if it isn’t able to turn its share prices around. | The telehealth giant's shares have closed below $1 on average for the past 30 days. The company said it would address the deficiency by effecting a reverse stock split.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
APRIL 5, 2024
Drug Topics sat down with Douglas Hoey, CEO of NCPA, at the 2024 AAP annual conference to discuss how independent pharmacies are doing so far this year.
Pharmacy Times
APRIL 5, 2024
These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.
Fierce Pharma
APRIL 5, 2024
After a short period of doubt, the FDA has followed the opinion of its advisers and moved Bristol Myers Squibb’s CAR-T therapy Abecma into the earlier treatment of multiple myeloma. | After a short period of doubt, the FDA has followed the opinion of its advisers and moved Bristol Myers’ CAR-T therapy Abecma into the earlier treatment of multiple myeloma.
STAT
APRIL 5, 2024
When Francis Collins, then-director of the National Human Genome Research Institute, testified before Congress in 2003 about the significance of sequencing the human genome that year, he introduced personalized medicine as a new concept. He predicted that in 10 years personalized medicine would allow physicians to employ “predictive genetic tests … so that each of us can learn of our individual risks for future illness and practice more effective health maintenance and disease prev
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
APRIL 5, 2024
Vertex CEO Reshma Kewalramani, M.D., made $20.6 million in 2023, which was an increase of 30% from her $15.9 million pay in 2022.
Pharmacy Times
APRIL 5, 2024
Despite being a Schedule I drug, cannabis is increasingly used in oncology for symptom management, although data remains limited.
Pharmaceutical Commerce
APRIL 5, 2024
In an interwith with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value and Access Advisor, Schoonveld Advisory, explains why pharmaceutical products tend to cost more in the US than the rest of the world.
European Pharmaceutical Review
APRIL 5, 2024
Interim data from a Phase I/II clinical trial suggest that mRNA-3927, an investigational mRNA therapy from Moderna, could be a promising treatment for propionic acidaemia. A 70 percent reduction in the risk of metabolic decompensation events was reported by eight participants in the 12-month pretreatment period, according to the trial results published in Nature. “We are excited to share the first published clinical data utilising an mRNA therapy for intracellular protein replacement,̶
Drug Topics
APRIL 5, 2024
Kathy Campbell, PharmD, pharmacist and patient advocate at Medicap Pharmacy in Owassa, Oklahoma, and CEO of DrKathy Health, discusses the unique value that a wellness-focused pharmacy offers compared to traditional models.
pharmaphorum
APRIL 5, 2024
Our regular round-up of financings in the biotech sector is headed by rumours of a $150 to $200 million initial public offering (IPO) for Aardvark Therapeutics, an emerging player in the weight-loss category, alongside a trio of big private rounds.
Fierce Pharma
APRIL 5, 2024
AstraZeneca's Imfinzi has delivered positive clinical data in another type of lung cancer, building on the immunotherapy’s existing FDA clearance in stage 3 non-small cell lung cancer and extensive | AstraZeneca's Imfinzi has delivered positive clinical data in another type of lung cancer, building on the immunotherapy’s existing FDA clearance in stage 3 non-small cell lung cancer and extensive-stage small cell lung cancer.
STAT
APRIL 5, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey! Meghana here. Today, we’re encouraging you to look elsewhere within the STAT universe for fantastic content. There’s, of course, our podcast , “The Readout Loud,” and Adam Feuerstein’s spicy new newsletter , “Adam’s Biotech Scorecard.
Fierce Healthcare
APRIL 5, 2024
Payer Roundup—Blue Cross Blue Shield Association lawsuit unfolds; Rightway raises $109M; Surescripts reportedly eyes sale ntong Fri, 04/05/2024 - 16:02
Fierce Pharma
APRIL 5, 2024
Amid ongoing drug shortages and other headline-grabbing issues that fall under the FDA’s purview, the House Committee on Oversight and Accountability is putting the agency’s commissioner Robert Cal | The April 11 hearing could be contentious, as the committee wants to “hold the commissioner accountable" for the FDA's action on drug shortages, among other issues, according to a statement from Chairman James Comer, R-Kentucky.
pharmaphorum
APRIL 5, 2024
ADRIATIC trial finds AstraZeneca's cancer immunotherapy Imfinzi improves survival in patients with limited-stage small cell lung cancer (SCLC)
The Guardian - Pharmaceutical Industry
APRIL 5, 2024
Testing of 40 types of bandages found 65% had alarming levels of ‘forever chemicals’ in adhesive flaps and pads that touch wounds Many popular US bandage brands contain alarming levels of toxic PFAS “forever chemicals”, new research suggests , raising questions about the products’ safety. Testing of 40 types of bandages made by companies such as Band-Aid, Curad, Walmart and CVS found 26 products, or 65%, contain alarming levels of a marker of PFAS.
STAT
APRIL 5, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we expect to catch up on our reading, promenade extensively with our official mascots, and hold another listening party with Mrs. Pharmalot. The rotation will likely include this , this , this , this and this.
pharmaphorum
APRIL 5, 2024
Advances in immunosuppression research may bring transplant patients closer to “one organ for life” Mike.
Fierce Pharma
APRIL 5, 2024
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction than | Facing lackluster Cyltezo sales, Boehringer Ingelheim will prune its ranks in the U.S. and adopt a different way of marketing its Humira biosimilar.
Pharmacy Times
APRIL 5, 2024
Pharmacy Times will be at the American Association of Psychiatric Pharmacists (AAPP) Annual Meeting in Orlando, Florida from April 7 to April 10, 2024.
The Checkup by Singlecare
APRIL 5, 2024
Ozempic (semaglutide) is a once-weekly injectable drug that is approved by the Food and Drug Administration (FDA) to lower blood sugar levels in people with Type 2 diabetes. GLP-1 receptor agonists like Ozempic also decrease appetite, so this drug is often prescribed off-label (a use that is not approved by the FDA) for weight loss. Because Ozempic may cause you to be less hungry and, therefore, lead you to eat less food than usual, it’s a good idea to fill your plate with nourishing, nutrient
Pharmacy Times
APRIL 5, 2024
The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.
Fierce Pharma
APRIL 5, 2024
After Novo Holdings set the stage for a $16.5 billion buyout of contract manufacturing giant Catalent earlier this year, its parent company is giving antitrust officials more time for their review | After Novo Holdings pitched a $16.5 billion buyout of Catalent in February, the companies have given the FTC extra time to review the deal.
Pharmaceutical Technology
APRIL 5, 2024
MiNA Therapeutics has entered into an agreement with Nippon Shinyaku to develop RNAa therapeutics for rare neurodegenerative ailments.
Expert insights. Personalized for you.
218 
Let's personalize your content